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Abstract
Background: Linac-based stereotactic radiosurgery or fractionated stereotactic radiotherapy (SRS/FSRT) of multiple brain
lesions using volumetric modulated arc therapy (VMAT) is typically performed by a multiple-isocenter approach, i.e. one
isocenter per lesion, which is time-demanding for the need of independent setup verifications of each isocenter. Here,
we present our initial experience with a new dedicated mono-isocenter technique with multiple non-coplanar arcs
(HyperArc™, Varian Inc.) in terms of a plan comparison with a multiple-isocenter VMAT approach.
Methods: From August 2017 to October 2017, 20 patients with multiple brain metastases (mean 5, range 2–10) have
been treated by HyperArc in 1–3 fractions. The prescribed doses (Dp) were 18–25 Gy in single-fraction, and 21–27 Gy
in three-fractions. Planning Target Volume (PTV), defined by a 2 mm isotropic margin from each lesion, had mean
dimension of 9.6 cm3 (range 0.5–27.9 cm3). Mono-isocenter HyperArc VMAT plans (HA) with 5 non-coplanar 180°-arcs
(couch at 0°, ±45°, ±90°) were generated and compared to multiple-isocenter VMAT plans (RA) with 2 coplanar 360°-arcs
per isocenter. A dose normalization of 100%Dp at 98%PTV was adopted, while D2%(PTV) < 150%Dp was accepted. All
plans had to respect the constraints on maximum dose to the brainstem (D0.5cm3 < 18 Gy) as well as to the optical
nerves/chiasm, eyes and lenses (D0.5cm3 < 15 Gy). HA and RA plans were compared in terms of dose-volume metrics, by
Paddick conformity (CI) and gradient (GI) index and by V12 and mean dose to the brain-minus-PTV, and in terms of MU
and overall treatment time (OTT) per fraction. OTT was measured for HA treatments, whereas for RA plans OTT was
estimated by assuming 3 min. For initial patient setup plus 5 min. For each CBCT-guided setup correction per isocenter.
Results: Significant variations in favour of HA plans were computed for both target dose indexes, CI (p < .01) and
GI (p < .01). The lower GI in HA plans was the likely cause of the significant reduction in V12 to the brain-minus-
PTV (p = .023). Although at low doses, below 2–5 Gy, the sparing of the brain-minus-PTV was in favour of RA
plans, no significant difference in terms of mean doses to the brain-minus-PTV was observed between the two
groups (p = .31). Finally, both MU (p < .01) and OTT (p < .01) were significantly reduced by HyperArc plans.
Conclusions: For linac-based SRS/FSRT of multiple brain lesions, HyperArc plans assured a higher CI and a lower GI
than standard multiple-isocenter VMAT plans. This is consistent with the computed reduction in V12 to the brain-minus-
PTV. Finally, HyperArc treatments were completed within a typical 20 min. time slot, with a significant time reduction
with respect to the expected duration of multiple-isocenters VMAT.
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Background
Brain metastases (BM) are the most common intracranial
tumors in adults: about 20–40% of patients affected by
cancer will develop BM during their oncological history [1]
and most of them have an oligometastatic disease. While
multiple brain metastatic patients were typically treated by
whole-brain radiotherapy (WBRT) in the past, in recent
years the role of single-fraction radiosurgery (SRS) and
fractionated stereotactic radiotherapy (FSRT) has gained
importance in the treatment of BM [2]. This practice-
changing approach has been driven by the evaluation of
increased risk of detriment in neurocognitive functions for
patients undergoing WBRT [3, 4], together with the absence
of improvement in overall survival (OS) [5, 6] as compared
to SRS/FSRT. Although SRS is now widely used for the
treatment of ≤4 BM in patients with a life expectancy of
more than 3–6 months [5, 7], Yamamoto et al. [8, 9] have
shown similar OS for patients with 5–10 BM when com-
pared to patients with 2–4 BM treated with SRS by Gamma
Knife™ (Elekta Inc., Stockholm, Sweden). This suggests that
the use of SRS/FSRT in patients with up to 10 BM might be
appropriate, by limiting this upper threshold of treatable
BM mainly by the duration of the treatment session [10].
Overall treatment time (OTT) remains an important
issue also for linac-based treatments, which are typic-
ally performed by multiple-isocenter VMAT plans with
one isocenter per lesion [11]. This translates into multiple
time-consuming imaging sessions for setup correction
(IGRT) corresponding to the number of isocenters. Imaging
sessions are mainly performed by CBCT, which takes up to
5 min for scanning, image registration and setup correction.
Therefore, an added time from IGRT to the beam-on time
of about 5 min. per lesion makes linac-based SRS/FSRT
unsuitable for patients with ≥5 BM. To support the use of
SRS/FSRT in patients with several BM, mono-isocenter
volumetric modulated arc therapy (VMAT) approaches with
multiple non-coplanar arcs have been proposed [11–14],
with the potential to treat multiple BM within a typical time
slot (about 20 min.) thanks to the use of one IGRT session.
HyperArc™ (Varian Medical System Inc., Palo Alto, CA,
USA), HA in the following, is a development of the mono-
isocenter VMAT approach to SRS/FSRT first proposed by
Clark et al. [11, 12], which assures a largely automated
optimization process, thanks to dedicated algorithms. In
August 2017, the first patients worldwide were treated with
HA SRS/FSRT in our institution.
Purpose of the present analysis is to report dosimetric
plan quality and OTT of single-isocenter HA plans as
compared to multiple-isocenter VMAT plans.
Methods
Patients
From August to October 2017, 20 patients with multiple
BM (mean 5, range 2–10) have received SRS/FSRT with
the new HA technique in 1–3 fractions. The prescribed
doses (Dp) were as follow: 18–25 Gy in a single-fraction
(if all BM had diameters smaller than 3 cm) [15]; and
21–27 Gy in three-fractions (for BM larger than 3 cm,
or if located adjacent to critical structures) [16]. SRS/
FSRT treatments were performed by a TrueBeam™ (Varian
Inc.) linac, equipped with a ‘Millenium’ 120-leaves MLC.
Although such MLC is composed of leaves of different
projected widths at isocenter (0.5 cm width for the central
portion of the treatment field, which is 20 cm height, and
1.0 cm width for the outer portions, 10 cm heights in each
direction), only central leaves (i.e., 0.5 cm width at isocen-
ter) were used by the here presented plans, even when
(HA plans) the jaw setting was automatically selected
from the system. Patients’ data are summarised in Table 1:
BM originated mostly from NSCLC (8/20) and breast
adenocarcinoma (7/20) as primary tumours.
For each patient a planning-CT scan without contrast
medium (CTp) was acquired in supine position, with
the Encompass™ (QFix, Avondale, PA – USA) mask and
Table 1 Patients’ gender, age, number of lesions, PTV total










1 F 54 7 6.8 18 1
2 M 54 5 3.7 25 1
3 M 48 3 11.5 27 3
4 F 61 8 27.9 24 3
5 M 53 3 3.4 25 1
6 F 74 2 5.2 27 3
7 F 56 5 3.3 25 1
8 M 67 3 4.2 27 3
9 F 37 3 7.2 27 3
10 F 46 6 20.8 21 3
11 M 58 3 1.9 27 3
12 F 52 4 0.5 21 3
13 F 67 7 13.1 27 3
14 F 77 9 18.9 27 3
15 M 71 2 7.4 25 1
16 M 54 2 3.4 24 3
17 F 50 5 6.9 25 1
18 F 68 7 4.1 24 1
19 F 55 3 19.6 27 3
20 M 55 10 21.7 27 3
m 58 5 9.6 25 2
sd 10 2 8.0 3 1
min 37 2 0.5 18 1
max 77 10 27.9 27 3
m, mean; sd, standard deviation; min, minimum value; max, maximum value
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support, and a slice thickness of 1 mm. The double
mask is made out of a very rigid thermoplastic material
and provides anterior and posterior cranial support,
thus minimizing the risk of inter/intra-fractional move-
ments. Further, the Encompass support system includes
radiopaque markers, which are used by the treatment
planning system (TPS) Eclipse™ (v. 15.5.07, Varian Inc.),
as described more in detail in the next section 2.2.
After co-registration with the CTp, the MRI scans (3D
spoiled-GRE T1) were used to contour the target
volumes and organs at risk (OARs). Gross tumor
volume (GTV) was defined as macroscopic contrast-
enhancing lesion on T1-MRI, and was assumed equal
to the clinical target volume (CTV). Planning target
volume (PTV) was then obtained by an isotropic 2 mm
margin from GTV, which is a common strategy to
minimize risk of geographical miss, as well as to
improve dosimetric accuracy, although it increases the
shell of healthy brain irradiated at high doses [17, 18].
The OARs considered for the optimization were: brain
(i.e., healthy brain-minus-PTV, BmP), eyes, lenses, optic
chiasm, optic nerves, brainstem and hippocampi. Volu-
metric dose prescription was adopted, by normalizing
100% Dp to 98% of the volume given by the union of all
the conceived PTVs (PTV_all), while large intra-tumour
dose heterogeneity D2%(PTV) < 150%Dp was accepted.
HyperArc and multiple-isocenters VMAT plans
HyperArc is an add-on of the Eclipse TPS which enables
the use of a mono-isococentric technique for the simultan-
eous irradiation of multiple BM on a TrueBeam (Varian
Inc.) linac. According to couch positions and arc lengths
HA plans adopt the same class-solution as in [12, 13],
which consists of a maximum of 5 non-coplanar arcs, based
on 4 of 5 possible fixed angular couch positions to be
selected between (0°, ±45°, + 90°) and (0°, ±45°, − 90°), with
each arc having a fixed length of 180°, as shown in Fig. 1.
HA provides a digital model of the patient support system
(Encompass, Q-Fix Inc.), which enables the prediction of
the clearance between the patient and the treatment
machine (TrueBeam, Varian Inc.), on an individual basis,
for each of the conceived non-coplanar arcs. In details,
once the target volumes are specified and the planning
isocenter is positioned at the barycentre of such set of
targets, a preliminary test is automatically performed to
estimate the position of the patient within the patient
positioning device with respect to the treatment machine.
This makes it possible to calculate, for the different angular
positions of the couch, the distance between the patient
and the treatment machine for each control point of all
arcs. This strategy avoids dummy runs prior to treatment
delivery at each different couch rotation and can drastically
reduce the necessary OTT per treatment fraction. In case
of a predicted potential collision for one of the arcs, it has
to be necessarily removed first to proceed with the
optimization phase. The optimization of the plan starts
with the selection of the optimal collimator angle for each
of the arcs, by a specific algorithm (CAO, Varian Inc.) that
aims to minimize the occurrence of high-dose bridges
between the different lesions. Within the framework of the
optimizer (PO, Varian Inc.) used by Eclipse, two other spe-
cific algorithms were introduced: first, SRS-NTO (Varian
Inc.), which reduces the dose to healthy surrounding brain
tissue (brain-minus-PTV) according to a user-selectable
weight, without the need of defining multiple concentric
ring-structures around each target volume, as previously
reported in the literature [12]. Second, ALDO (Varian
Inc.), which assures that each target is covered by its
prescribed dose, even in case of variable Dp values
because HA allows for different prescribed doses to
different lesions in the same patient (although in this
study all plans were based on one and the same Dp
value for all the lesions of each patient).
According to the planning approach we adopted to
generate the here presented HA plans, we always started
by letting CAO to automatically select the collimator
angles for each arc. Then, we used the pre-defined
weights which are proposed by the system for its new
tools. ALDO, which allows that only lower-dose con-
straints be assigned to the targets, was used with a fixed
weight equal 100 for each target. The fact that ALDO
Fig. 1 Typical beam arrangement of an HyperArc™ plan: five
non-coplanar 180°-arcs at four angular positions of the couch (0°,
±45°, 90°)
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does not allow to limit the upper dose to the targets was
not critical for our plans, because we are used to accept
as large intra-tumour dose heterogeneity as D2%(PTV) <
150%Dp, but such an approach might be problematic in
centres were a lower intra-tumour dose heterogeneity is
accepted. The same weight, 100, was used for SRS-NTO
also. No other structures/objectives were included in this
first trial of optimization. After dose calculation, the so
resulting dose distributions were generally satisfying all
our necessary constraints for planning approval.
However, in the few cases where, as the result of the
adjacency between a lesion and an OAR, the maximum
dose constraint to the OAR had not been assured, the
optimization was repeated by user control. ALDO was
now unselected, by letting the user to insert one or more
upper-dose constraints to the lesion/lesions, and upper-
dose constraints to the involved OAR were added too.
For planning approval, all plans had to respect the OAR
constraints for maximum dose, referred to the hottest
0.5 cm3 (D0.5cm3). For single fraction (three-fractions)
SRS, D0.5cm3 had to be lower than 10 (18) Gy, for the
brainstem, and lower than 8 (15) Gy, for the eyes, lenses,
optic chiasm, and optic nerves. Further, mean dose to
the hippocampi had to be lower than 5 (7) Gy [19].
Before the treatment of each patient both a dosimetric
verification in phantom and isocenter fidelity checks
were performed. For individual dosimetric verification, a
planar array of ionization chambers (Octavius™, PTW
Inc.) was aligned first at the isocentric plane, which
generally does not include any lesion and is hence useful
for testing the range of medium to low doses, and then
to a second plane, chosen to include the maximum
number of almost coplanar lesions (at least one) and
thus testing the high dose range. For isocenter fidelity
checks one automatic procedure (MPC™, Varian Inc.),
which is proposed by the manufacturer, was performed
which tests the mechanical isocenter until maximum
couch rotations (±90°) within a 10-min. time slot.
Before HA was implemented, in our center multiple BM
were treated by multiple-isocenter RapidArc™ (Varian
Inc.) VMAT plans (RA). Such RA plans consisted of 2
coplanar 360°-arcs per isocenter, with a fixed collimator
angle (±10°) planned with Eclipse TPS. A couple of
concentric rings, each 8 mm wide, were used to force the
optimizer to create steep dose gradients around each
lesion. In the present study, HA and RA plans were opti-
mised for each patient, by the use of the same optimizer
(PO, v.15.5.07) and dose calculation algorithm (AAA,
v.15.5.07), with the same dose grid resolution (1 mm).
Dose-volume and efficiency metrics
In terms of sparing of the brain-minus-PTV (BmP) the
V12 (the volume receiving no less than 12 Gy) was used
as a metric of plan quality, since a correlation between
the extent of intermediate dose spill (e.g., V12) to the
BmP and the risk of radionecrosis has previously been
reported for cranial SRS/FSRT [20–22]. The mean dose
(Dmean) to the BmP was also analysed, as we believe that
minimising the Dmean(BmP) is advisable, regarding the
higher re-treatment rates in patients with multiple BM
treated with SRS.
According to target dose coverage, both the Paddick
conformity index (CI), and the Paddick gradient index
(GI) were used [23]. CI is defined by CI = (PTVDp/
PTV)* (PTVDp/ VDp), where PTVDp is the fraction of
PTV covered by the prescription isodose, and VDp is the
prescription isodose volume (cm3). According to our
dose normalization PTVDp/ PTV = 0.98, hence CI is re-
duced to 0.98* (0.98* PTV/ VDp). GI is defined by GI =
V50%Dp/ VDp, i.e. the ratio of the volumes delimited by
the 50%Dp and the 100%Dp isodoses. The GI describes
the steepness of the dose gradient from high (Dp) to
medium (50%Dp) dose levels and is a valid surrogate to
evaluate the extent of the intermediate dose spill which
impacts the V12(BmP) and therefore the risk of radione-
crosis [20–22].
The total number of monitor units (MU) and the overall
treatment time (OTT) per fraction were also considered
as indicators of efficiency in irradiation and in treatment
time, respectively. Whereas measured for HA treatments,
for RA plans OTT (min.) was estimated by assuming
3 min. for initial patient setup plus 5 min. per each
CBCT-guided setup correction per isocenter.
Statistics
HA and RA plans were compared in terms of the above-
mentioned dose-volume metrics: Paddick conformity
and gradient index for the target volumes and V12 and
Dmean for the healthy brain tissue (BmP). The total num-
ber of monitor units and the overall treatment time per
fraction, as efficiency indicators, were also compared.
For each parameter, the two HA and RA samples were
first tested for normality of distribution by Lilliefors test.
Then, according to the results of such preliminary test,
compared by a non-parametric Wilcoxon signed-rank
test, or by a parametric t-test. All computations, at the
0.05 level for statistical significance, were performed by
XLSTAT (v. 7.5.2, Addinsoft Inc.) add-on for Excel™
(Microsoft Inc.).
Results
All patients were safely treated without interruption
during treatment from any interlock related to the risk
of a potential collision, although no dummy run was
performed before the non-coplanar arcs. Dosimetric
verification in phantom resulted in a passing-rate of not
lower than 90%, 95%, for a γ-index computed at (2 mm,
2%), (3 mm, 3%), for all patients [24].
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In Table 2 the values of the plan quality metrics, for
both RA and HA plans, are reported for all patients.
Results from hypothesis testing are reported below. For
both target dose indexes significant improvements in
favour of HA plans were achieved. While mean (± sd)
CI value increased significantly from (0.87 ± 0.07) for RA
plans, to (0.96 ± 0.02) for HA plans (p < .01), the GI
value significantly reduced from (6.08 ± 2.24) for RA
plans, to (4.41 ± 1.18) for HA plans (p < .01). To outline
such improvement in GI from the HA plans, in Fig. 2
the spatial dose distribution between the 50%Dp and
100%Dp isodose levels is shown for a representative
patient.
The better GI in HA plans was most likely the cause
of the significant reduction in V12(BmP): from (42.2 ±
40.8) cm3 for RA plans, to (23.6 ± 23.6) for HA plans
(p = .023). While the results for V12 suggested that a
better dose sparing of the BmP at the medium-to-high
dose range is assured from the HA plans, the DVH
curves of the BmP always exhibited an improved spar-
ing from RA plans at low doses, typically below 2–5 Gy
according to Dp and number of BM, as shown in Fig. 3
for a representative patient. Consistently, no significant
difference between the Dmean(BmP) of the HA, (2.98 ±
1.47) Gy, and the RA, (2.62 ± 1.58) Gy, plans were reg-
istered (p = .31).
According to the indicators of efficiency in irradiation
and in treatment time, significant improvements were
found for HA plans. The total number of monitor units
per fraction significantly reduced from (15150 ± 11535)
for RA plans to (4313 ± 2292) for HA plans (p < .01).
Similarly, the overall treatment time per fraction signifi-
cantly reduced from (35 ± 15) min. For RA plans to (11
± 1) min. For HA plans (p < .01).
Discussion
The present study reports the worldwide first clinical
usage of the HyperArc SRS/FSRT-technique. All patients
Table 2 Values of the plan quality metrics and results from hypothesis testing
Dmean
BmP (Gy) V12
BmP (cm3) CI Paddick GI Paddick MU (/ fraction) OTT (min)
Pt.#\ Plan RA HA RA HA RA HA RA HA RA HA RA HA
1 2.48 2.73 12.7 5.9 0.89 0.95 6.56 4.71 35,900 6905 57 14
2 2.17 2.45 21.6 8.9 0.80 0.98 6.84 4.69 32,921 7601 46 15
3 2.66 2.96 49.5 29.4 0.90 0.92 4.51 3.41 7643 2345 22 12
4 5.04 5.03 100.0 44.3 0.93 0.99 6.40 3.59 12,094 2712 50 12
5 1.51 1.71 15.7 7.7 0.88 0.97 6.09 4.25 22,388 6813 30 15
6 1.26 1.70 18.7 12.3 0.95 0.97 4.50 3.60 3947 2231 15 12
7 1.81 2.15 23.9 9.9 0.83 0.98 7.80 5.02 18,755 6236 38 14
8 1.85 2.15 23.5 13.3 0.91 0.98 5.80 4.24 6070 2421 21 12
9 2.49 2.83 28.1 20.4 0.92 0.94 3.82 4.61 6316 2221 21 12
10 3.1 4.02 34 25.1 0.93 0.93 4.15 3.36 8601 2928 38 13
11 1.03 1.86 12.3 6.1 0.88 1.00 6.66 4.7 6011 2778 21 13
12 0.66 0.75 4.8 1.7 0.72 0.96 14.3 8.85 5109 2311 26 12
13 4.68 4.61 66.6 31.3 0.80 0.93 5.44 3.92 14,506 3335 46 13
14 6.13 6.16 152.1 86.6 0.88 0.93 7.49 4.84 12,679 3842 55 13
15 1.86 1.82 22.9 13.9 0.93 0.96 4.69 3.49 13,069 5597 20 14
16 0.74 1.43 10.9 7.5 0.94 0.97 4.72 3.87 3617 2253 15 12
17 2.72 2.92 28.5 13.7 0.79 0.97 5.33 3.98 27,429 7843 43 15
18 2.32 3.00 25.9 12.0 0.69 0.94 6.30 5.01 42,737 9094 61 16
19 2.14 3.46 61.9 41.2 0.92 0.95 4.23 3.57 6276 2599 21 11
20 5.71 5.77 129.6 80.3 0.88 0.92 6.08 4.45 16,933 4197 57 13
mean 2.62 2.98 42.2 23.6 0.87 0.96 6.08 4.41 15,150 4313 35 11
sd 1.58 1.47 40.8 23.6 0.07 0.02 2.24 1.18 11,535 2292 15 2
min 0.66 0.75 4.8 1.7 0.69 0.92 3.82 3.36 3617 2221 15 9
max 6.13 6.16 152.1 86.6 0.95 1.00 14.3 8.85 42,737 9094 61 15
p = .310 § p =.047§; p = .023‡ p < .01§; p < .01‡ p < .01 §; p < .01‡ p <.01§; p < .01‡ p < .01§; p < .01‡
m, mean; sd, standard deviation; min, minimum value; max, maximum value. Bold characters are used for p-values when statistical significance resulted from
2-tails (§), or 1-tail (‡) U Mann-Whitney test
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were safely treated by HA within their scheduled 20 min
time slot including CBCT for setup correction. This was
made possible by a digital model which includes both,
the patient within the Encompass positioning setup
system and the TrueBeam gantry head, and is able to
predict the clearance between patient and linac for any
control point of each non-coplanar arc.
To evaluate the improvements associated with the new
HA technique with respect to multiple-isocenter VMAT
approach (RA) to multiple BM, a comparative RA plan
was generated for every patient. Noteworthy, whereas an
experienced physicist is required for multi-isocenter RA
plans, mono-isocenter HA plans can be generated
largely automatized. The HA software selects the isocen-
ter at the center of mass of all BM lesions, and sets the
collimator angle for each arc; then, a predefined set of
weighted constraints is proposed for dose optimization,
which is supported by two specific algorithms (ALDO
and SRS-NTO).
According to target dose coverage, the Paddick con-
formity index shows how conformal and overlapping the
prescription isodose is with respect to the PTV. Hence,
the CI value is a surrogate for the probability of local
control and the ability to spare adjacent critical serial
OARs. By contrast, the Paddick gradient index describes
how enlarged the 50%Dp isodose is with respect to the
prescription isodose, thus describing the extent of the
medium-to-high-dose shell around the PTV.
By considering that in our sample Dp was equal to (25
± 3) Gy, and thus 50%Dp is about equal to 12.5 Gy, a
large GI directly translates into large dose spills, roughly
between 12.5 and 25 Gy. This can directly be associated
with an increased V12(BmP), which is related to the risk
of radionecrosis [20–22], underlining the importance of
a possibly small GI value. In cases of single-lesion SRS,
an optimal value for GI of ≤3 was suggested from
Paddick et al. [23]. For SRS of multiple BM, a larger
upper limit for optimal GI seems still reasonable, even if
the definition of an exact threshold remains challenging.
In our sample the mean GI for HA plans was (4.41 ±
1.18), which is higher than 3, but still largely lower than
the mean GI we obtained for RA multiple-isocenters
plans (6.08 ± 2.24). Furthermore, in our preliminary
experience with single-lesion HA plans we obtained a
mean GI equal to (3.3 ± 0.8) (unpublished data), which is
strictly consistent with the value reported from Clark et
al. [12], i.e. (3.3 ± 0.4). Finally, our mean GI (4.41) is con-
sistent with the 4.77 value reported in [25] for 3–4 BM
with a range in total target size of (0.1–10.5) cm3. We
believe this supports the high quality of plans produced
by HA and that an upper threshold for optimal GI
around 3.5–4.5, as a function of the number of/ distance
between lesions and their absolute volume, seems rea-
sonable for multiple BM.
According to dose sparing of healthy brain tissue, the
mean value obtained for V12(BmP) by HA plans was
almost halved when compared to RA plans ((23.6 ± 23.6)
cm3 vs (42.2 ± 40.8) cm3), even if it remained still dou-
bled with respect to the generally recommended 10 cm3
threshold for single lesion SRS [20–22]. However, if we
Fig. 2 Computed dose distributions, here depicted in colourwash from 50%Dp to 100%Dp, from HA (left) and RA (right) plans for an example patient.
The typical enlargement of the 50%Dp isodose-shell around the targets for the RA plan, which may bring to the formation of dose-bridges in case of
adjacent lesions, is shown
Ruggieri et al. Radiation Oncology  (2018) 13:38 Page 6 of 9
restricted our computations to the 11/20 patients which
had a total PTV not larger than 7 cm3, which reflects a
mean number of 4 lesions as in [13], the mean value of
V12(BmP) obtained with HA plans was equal to (9.0 ±
3.7) cm3. Further, if a per-lesion-V12(BmP) is computed
for each patient by the ratio of V12(BmP) over the
number of BM, similarly to Clark et al. [11], an average
per-lesion-V12(BmP) equal to (4.9 ± 3.5) cm
3 results
which satisfies the above 10 cm3 threshold for single
lesion SRS. Thus, HA seems well performing in terms of
volume reduction for the medium-to-high dose shells
around the targets.
No significant difference between HA and RA plans
was computed for Dmean(BmP), likely as the result of the
increased mean paths from skin to target by the non-
coplanar arcs, which holds in particular for lesions
located in the posterior fossa.
A quite improved efficiency in irradiation was ob-
served, with a mean number of MU for HA plans
reduced to less than one third as compared to RA plans.
This could have compensated the above-mentioned
increase in the mean path from skin to target by the
non-coplanar arcs, thus determining an equivalent
Dmean(BmP).
The significant reduction from HA plans in the overall
treatment time per fraction (OTT) is of high clinical
relevance regarding patient comfort and higher patient
throughput, because with a mean OTT of (11 ± 2) min.,
HA treatments can be easily scheduled within a typical
20 min time slot on the treatment machine. Further-
more, HA is a fast treatment modality, independent of
the number of treated BM lesions: even for patients with
5 or more lesions, for which treatments with multiple
isocenters (RA) would take about 40 min or more.
Conclusions
For linac-based SRS/FSRT of multiple brain lesions,
mono-isocenter HA plans performed better than multi-
isocenter VMAT plans in terms of both dose-volume
quality metrics and OTT. A clinical analysis of patients’
response to treatment, focused on local control, appear-
ance of new brain metastases and overall survival, is
ongoing and will be the subject of a next report.
Fig. 3 Cumulative dose volume histograms of PTV_all and OARs, from HA and RA plans, for a patient with five lesions. The typical intersection of
cDVH curves for the Brain-minus-PTV is illustrated
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By considering that HyperArc produces high quality
plans in a largely automated way, and enables an avoid-
ance of collision of patient-on-couch and gantry, and
that all treatments were completed within a typical
20 min. time slot, this analysis showed that HyperArc
may offer an easy and safe alternative to multi-isocenter
VMAT for complex SRS/FSRT for multiple BM.
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